"Not slow at all"! At present, 5 vaccines have entered the second phase of clinical trials in China! Zhong Nanshan, director of the national respiratory disease clinical research center of the First Affiliated Hospital of Guangzhou Medical University and academician of the Chinese Academy of engineering, said in an interview on the evening of 29thChina is in the first place in vaccine research and development in the world. At present, five vaccines have entered the second phase of clinical trials.
He said :" Whether it's a RNA vaccine or an all - viral inactivated vaccine, Now we've got five models in phase two, and we' re not slow at all.Of course, vaccine development still takes a long time, a very efficient vaccine to choose through comparison, so the time will be longer. But I feel that, in the current process, by the end of this year, some of the emergencies (situations) should be completely solvable.
Recently, China's new coronavirus vaccine research and development on the news.
Sinopharm China biology: new coronavirus inactivated vaccine is expected to be launched at the end of this year or early next year
In the early morning of May 30, the official microblog of the state owned assets supervision and Administration Commission of the State Council announced that up to now, Sinopharm Wuhan Institute of biological products and Beijing Institute of biological products have completed phase I and phase II of the new inactivated vaccine, and more than 2000 people have received the vaccine injection. Clinical data show that,vaccinesSafety and effectivenessobtainFull verification,Incidence of adverse reactionsAnd degreeAll of them are far lower than the vaccines on the market。 It is reported that the clinical trials are divided into three phases, I-III clinical trials are completed until the market is launched, and it is expected to be completed as soon as the end of this year or the beginning of next year.
Photo source: microblog of SASAC
It is reported that in order to verify the safety and effectiveness of the new crown inactivated vaccine and help the early listing of the new crown inactivated vaccine, Sinopharm group also conducted vaccine pre-test.The pre-test showed that the antibody of the subjects had completely reached the level of resistance to the new coronavirus, and the positive conversion rate of the new coronavirus antibody was 100%, indicating that the vaccine was safe and effective.
The results of the new crown vaccine test of academician Chen Wei's team: safe and can induce immune response
In addition, a week ago, the Chinese research team reported in the lancet, a British Medical Journal, that they had carried out a phase I clinical trial of a new coronavirus vaccine, which showed that the vaccine was safe and could induce a rapid immune response. The clinical trial was carried out by a team led by academician Chen Wei of the Institute of bioengineering, Academy of military medicine, Academy of Military Sciences. The vaccine used in the experiment is a recombinant coronavirus vaccine with adenovirus vector.
The report said that within 28 days after vaccination, the vaccine showed good tolerance in different dose groups and did not cause serious adverse reactions. In a press release released by the lancet, Chen Wei said that phase 1 clinical trials showed that vaccination with the adenovirus vector recombinant new coronavirus vaccine could induce the production of virus-specific antibodies and T cells within 14 days, "these results represent an important milestone.".
The daily economic news includes the official news of the state owned assets supervision and Administration Commission of the State Council